Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Refractory Neuroendocrine Carcinoma

MedGen UID:: 1719330
•Concept ID:: C5237419
•: Neoplastic Process

Definition

Neuroendocrine carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVRefractory Neuroendocrine Carcinoma

Disease
- Neoplasm
  - Epithelial neoplasm
    - Carcinoma
      - Adenocarcinoma
        Neuroendocrine carcinoma
        Refractory Neuroendocrine Carcinoma
        Refractory Digestive System Neuroendocrine Carcinoma
        Refractory Pancreatic Neuroendocrine Carcinoma
        Refractory Lung Small Cell Carcinoma
        Platinum-Resistant Lung Small Cell Carcinoma
        Refractory Extensive Stage Lung Small Cell Carcinoma
        Refractory Merkel Cell Carcinoma
        Refractory Thyroid Gland Medullary Carcinoma

Professional guidelines

PubMed

Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.

Lin AL, Rudneva VA, Richards AL, Zhang Y, Woo HJ, Cohen M, Tisnado J, Majd N, Wardlaw SL, Page-Wilson G, Sengupta S, Chow F, Goichot B, Ozer BH, Dietrich J, Nachtigall L, Desai A, Alano T, Ogilive S, Solit DB, Bale TA, Rosenblum M, Donoghue MTA, Geer EB, Tabar V
Acta Neuropathol 2024 May 17;147(1):85. doi: 10.1007/s00401-024-02736-8. PMID: 38758238 Free PMC Article

The Evolving Treatment Landscape of Merkel Cell Carcinoma.

Singh N, McClure EM, Akaike T, Park SY, Huynh ET, Goff PH, Nghiem P
Curr Treat Options Oncol 2023 Sep;24(9):1231-1258. Epub 2023 Jul 5 doi: 10.1007/s11864-023-01118-8. PMID: 37403007 Free PMC Article

Treatment of Aggressive Thyroid Cancer.

Huang J, Harris EJ, Lorch JH
Surg Pathol Clin 2019 Dec;12(4):943-950. doi: 10.1016/j.path.2019.08.004. PMID: 31672300

See all (21)

Recent clinical studies

Etiology

Merkel Cell Carcinoma.

Strong J, Hallaert P, Brownell I
Hematol Oncol Clin North Am 2024 Oct;38(5):1133-1147. Epub 2024 Jul 26 doi: 10.1016/j.hoc.2024.05.013. PMID: 39060119 Free PMC Article

Theranostics of Thyroid Cancer.

Giovanella L, Tuncel M, Aghaee A, Campenni A, De Virgilio A, Petranović Ovčariček P
Semin Nucl Med 2024 Jul;54(4):470-487. Epub 2024 Mar 19 doi: 10.1053/j.semnuclmed.2024.01.011. PMID: 38503602

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.

Kaur J, Vijayvergia N
Curr Oncol 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. PMID: 37754542 Free PMC Article

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201

Everolimus.

Hasskarl J
Recent Results Cancer Res 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. PMID: 30069763

See all (67)

Diagnosis

Merkel Cell Carcinoma.

Strong J, Hallaert P, Brownell I
Hematol Oncol Clin North Am 2024 Oct;38(5):1133-1147. Epub 2024 Jul 26 doi: 10.1016/j.hoc.2024.05.013. PMID: 39060119 Free PMC Article

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.

Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942 Free PMC Article

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

DLL3: an emerging target in small cell lung cancer.

Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500 Free PMC Article

Merkel cell carcinoma.

Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P
Nat Rev Dis Primers 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. PMID: 29072302 Free PMC Article

See all (79)

Therapy

Merkel Cell Carcinoma.

Strong J, Hallaert P, Brownell I
Hematol Oncol Clin North Am 2024 Oct;38(5):1133-1147. Epub 2024 Jul 26 doi: 10.1016/j.hoc.2024.05.013. PMID: 39060119 Free PMC Article

Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.

Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M
Biochim Biophys Acta Rev Cancer 2023 Jul;1878(4):188928. Epub 2023 May 29 doi: 10.1016/j.bbcan.2023.188928. PMID: 37257629

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

Immunotherapy for Non-melanoma Skin Cancer.

Shalhout SZ, Emerick KS, Kaufman HL, Miller DM
Curr Oncol Rep 2021 Aug 27;23(11):125. doi: 10.1007/s11912-021-01120-z. PMID: 34448958 Free PMC Article

DLL3: an emerging target in small cell lung cancer.

Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K
J Hematol Oncol 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PMID: 31215500 Free PMC Article

See all (138)

Prognosis

Aggressive pituitary tumors (PitNETs).

Nishioka H
Endocr J 2023 Mar 28;70(3):241-248. Epub 2023 Mar 3 doi: 10.1507/endocrj.EJ23-0007. PMID: 36858483

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.

Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H
Cell Rep 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088. PMID: 31018139

Merkel cell carcinoma.

Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P
Nat Rev Dis Primers 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. PMID: 29072302 Free PMC Article

Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.

Ciarallo A, Marcus C, Taghipour M, Subramaniam RM
PET Clin 2015 Apr;10(2):265-78. Epub 2015 Jan 29 doi: 10.1016/j.cpet.2014.12.009. PMID: 25829091

See all (83)

Clinical prediction guides

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.

Yang C, Ma S, Zhang J, Han Y, Wan L, Zhou W, Dong X, Yang W, Chen Y, Gao L, Cui W, Jia L, Yang J, Wu C, Wang Q, Wang L
Proc Natl Acad Sci U S A 2024 Jun 4;121(23):e2317790121. Epub 2024 May 30 doi: 10.1073/pnas.2317790121. PMID: 38814866 Free PMC Article

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.

Kaur J, Vijayvergia N
Curr Oncol 2023 Sep 21;30(9):8653-8664. doi: 10.3390/curroncol30090627. PMID: 37754542 Free PMC Article

Aggressive pituitary tumors (PitNETs).

Nishioka H
Endocr J 2023 Mar 28;70(3):241-248. Epub 2023 Mar 3 doi: 10.1507/endocrj.EJ23-0007. PMID: 36858483

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).

Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J
Neuroendocrinology 2020;110(11-12):988-993. Epub 2020 Jan 2 doi: 10.1159/000505550. PMID: 31986515

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.

Beukhof CM, Brabander T, van Nederveen FH, van Velthuysen MF, de Rijke YB, Hofland LJ, Franssen GJH, Fröberg LAC, Kam BLR, Visser WE, de Herder WW, Peeters RP
BMC Cancer 2019 Apr 5;19(1):325. doi: 10.1186/s12885-019-5540-5. PMID: 30953466 Free PMC Article

See all (67)

Recent systematic reviews

Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.

Jing R, Wu N, Wu Y, Zhang Q, Liang Q, Huang P, Yi S
J Clin Endocrinol Metab 2024 Sep 16;109(10):2658-2672. doi: 10.1210/clinem/dgae454. PMID: 38970485

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.

Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME
BMC Cancer 2021 May 20;21(1):579. doi: 10.1186/s12885-021-08257-x. PMID: 34016077 Free PMC Article

Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.

Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E
J BUON 2019 Mar-Apr;24(2):415-423. PMID: 31127985

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D
World J Gastroenterol 2015 Feb 14;21(6):1945-55. doi: 10.3748/wjg.v21.i6.1945. PMID: 25684964 Free PMC Article

New therapeutic options for advanced forms of thyroid cancer.

Bernet V, Smallridge R
Expert Opin Emerg Drugs 2014 Jun;19(2):225-41. Epub 2014 Mar 3 doi: 10.1517/14728214.2014.894017. PMID: 24588376

See all (6)

MedGen

National Center for Biotechnology Information

Send to:

Refractory Neuroendocrine Carcinoma

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Practice guidelines

Related information

Recent activity